These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 17640385)

  • 21. Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
    Rinfret S; Behlouli H; Eisenberg MJ; Humphries K; Tu JV; Pilote L
    Am Heart J; 2008 Feb; 155(2):316-23. PubMed ID: 18215603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No effect of atorvastatin and simvastatin on oxidative stress in patients at high risk for cardiovascular disease.
    Scheffer PG; Schindhelm RK; van Verschuer VM; Groenemeijer M; Simsek S; Smulders YM; Nanayakkara PW
    Neth J Med; 2013 Sep; 71(7):359-65. PubMed ID: 24038561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study.
    Bang CN; Gislason GH; Greve AM; Torp-Pedersen C; Køber L; Wachtell K
    Eur J Prev Cardiol; 2014 Mar; 21(3):330-8. PubMed ID: 23012689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin.
    Jacobson TA; Wertz DA; Kuznik A; Cziraky M
    Curr Med Res Opin; 2013 Jul; 29(7):773-81. PubMed ID: 23647370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
    Strandberg TE; Holme I; Faergeman O; Kastelein JJ; Lindahl C; Larsen ML; Olsson AG; Pedersen TR; Tikkanen MJ;
    Am J Cardiol; 2009 May; 103(10):1381-5. PubMed ID: 19427432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
    Freeman SR; Drake AL; Heilig LF; Graber M; McNealy K; Schilling LM; Dellavalle RP
    J Natl Cancer Inst; 2006 Nov; 98(21):1538-46. PubMed ID: 17077356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after successful cardioversion.
    Naji F; Suran D; Kanic V; Vokac D; Sabovic M
    Int Heart J; 2009 Mar; 50(2):153-60. PubMed ID: 19367026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies.
    Arsenault BJ; Boekholdt SM; Hovingh GK; Hyde CL; DeMicco DA; Chatterjee A; Barter P; Deedwania P; Waters DD; LaRosa JC; Pedersen TR; Kastelein JJ;
    Circ Cardiovasc Genet; 2012 Feb; 5(1):51-7. PubMed ID: 22135385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
    Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH
    Am J Manag Care; 2007 Dec; 13 Suppl 10():S270-5. PubMed ID: 18095777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences between statins on clinical endpoints: a population-based cohort study.
    Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
    Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.
    Perreault S; Blais L; Dragomir A; Bouchard MH; Lalonde L; Laurier C; Collin J
    Eur J Clin Pharmacol; 2005 Oct; 61(9):667-74. PubMed ID: 16151763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
    Gresser U; Gathof BS
    Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
    Päivä H; Thelen KM; Van Coster R; Smet J; De Paepe B; Mattila KM; Laakso J; Lehtimäki T; von Bergmann K; Lütjohann D; Laaksonen R
    Clin Pharmacol Ther; 2005 Jul; 78(1):60-8. PubMed ID: 16003294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.
    Neuhaus O; Hartung HP
    Expert Rev Neurother; 2007 May; 7(5):547-56. PubMed ID: 17492904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study.
    Ghayour-Mobarhan M; Lamb DJ; Vaidya N; Livingstone C; Wang T; Ferns GA
    Angiology; 2005; 56(1):61-8. PubMed ID: 15678257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits and menaces related to the use of statins in patients after renal transplantation.
    Chmielewski M; Zdrojewski Z; Rutkowski B
    Ann Transplant; 2002; 7(2):6-10. PubMed ID: 12416466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia.
    Farnier M; Portal JJ; Maigret P
    J Cardiovasc Pharmacol Ther; 2000 Jan; 5(1):27-32. PubMed ID: 10687671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
    Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer.
    Huang BZ; Chang JI; Li E; Xiang AH; Wu BU
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.